LY2780301
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for LY2780301, covering 2016-07-12 to 2026-04-21. Get the full timeline:
Most recent: Clinical Trial Update: Phase Ib/II Study of LY2780301 in Combination With Weekly PACLITAXEL in HER2-metastatic Breast Cancer [Phase 1, Phase 2]